Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by Pareto8020on Jun 01, 2021 7:23am
181 Views
Post# 33301617

Tick Tock SBM

Tick Tock SBM
Wonder if SBM still "anticipates" the achieving the below milestones during the next TWO months?  Remember when they said they were close on the animal deal before Christmas?  Well here we are going into June and still radio silence and no tangible deals, results or anything from Howie yet.  Time to produce or get out of the way - it is embarassing how bad they are at managing this company in everyway possible.   

• Finalize due diligence and agree on terms with new organization in China
• Complete an additional licensing agreement for the SGLT2 inhibitor in new markets
• Secure non-dilutive funding through anticipated collaborations
• Finalize Tinyi agreement
• Complete Phase I clinical trial in China for the SGLT2 Inhibitor and advance to Phase II
<< Previous
Bullboard Posts
Next >>